Product image of Nilotinib Al (Nilotinib) supplied by GNH India

Nilotinib Al

Active Ingredient:
Nilotinib
Origin:
EU

Nilotinib Al (Nilotinib)

Nilotinib, the active ingredient in Nilotinib Al, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients and works by targeting molecular pathways that drive malignant cell growth, offering a targeted therapy option for this hematologic malignancy.

GNH India supplies Nilotinib Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, adhering to stringent quality standards and providing reliable logistics to ensure product integrity across global markets.

Manufacturer / TM Owner

Aliud Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nilotinib is a targeted therapy used in the management of chronic myeloid leukemia and its disease phases.

  • Chronic phase CML: reduces leukemic cell proliferation and improves hematologic response.
  • Accelerated phase CML: helps achieve cytogenetic and molecular remission.
  • Blast phase CML: used as part of combination regimens to control aggressive disease.

How It Works

  • Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, as well as PDGFR and c‑KIT receptors. By blocking these kinases, it interferes with downstream signaling pathways that promote malignant cell proliferation and survival, leading to reduced growth of leukemic cells in chronic myeloid leukemia.

Side Effects

Adverse reactions to nilotinib may vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: loose stools that may require hydration.
  • Rash: skin irritation or erythema.
  • Fatigue: generalized tiredness.
  • Headache: mild to moderate head pain.
  • Myalgia: muscle aches.

Serious or Rare Side Effects

  • QT interval prolongation: risk of cardiac arrhythmia.
  • Pancreatitis: inflammation of the pancreas.
  • Hepatic toxicity: elevated liver enzymes or hepatitis.
  • Severe neutropenia: marked reduction in neutrophil count.
  • Thrombocytopenia: low platelet levels increasing bleeding risk.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Precautions & Warnings

When prescribing nilotinib, clinicians should observe several safety measures.

  • Monitor cardiac function: obtain baseline ECG and repeat periodically.
  • Assess liver enzymes: check hepatic function before and during therapy.
  • Check blood counts: monitor for neutropenia, thrombocytopenia, and anemia.
  • Avoid concomitant QT‑prolonging drugs: reduce risk of arrhythmia.
  • Store at room temperature: keep in the original pack, protect from moisture and light.

Avoid Interactions

Nilotinib may interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): increase nilotinib exposure.
  • Antacids containing aluminum or magnesium: reduce nilotinib absorption.
  • QT‑prolonging agents (e.g., sotalol): additive risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inducers (e.g., rifampin): decrease nilotinib plasma levels.
  • Warfarin: may require INR monitoring and dose adjustment.

Frequently Asked Questions

Nilotinib Al contains the active ingredient nilotinib, which is prescribed for the treatment of chronic myeloid leukemia (CML) in adult patients. It targets the BCR‑ABL fusion protein that drives the disease, helping to control leukemic cell growth and improve clinical outcomes.

Nilotinib works by selectively inhibiting the BCR‑ABL tyrosine kinase, as well as PDGFR and c‑KIT receptors. This blockade interrupts signaling pathways essential for malignant cell proliferation and survival, thereby reducing the expansion of leukemic cells in patients with CML.

The dosage of Nilotinib Al is determined individually by the prescribing physician based on the patient’s disease phase, response to therapy, and overall health status. Only a qualified healthcare professional can set the appropriate dose and schedule.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while on therapy. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and selectivity compared with first‑generation agents such as imatinib. It may achieve faster and deeper molecular responses, but the choice of therapy depends on individual patient factors, mutation profile and tolerability.

Nilotinib Al should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Nilotinib Al is taken orally, usually once daily with a low‑fat meal to enhance absorption. The tablets should be swallowed whole with water and not crushed or chewed. Patients must follow the dosing schedule prescribed by their healthcare provider.

The most serious risks include QT interval prolongation, which can lead to serious cardiac arrhythmias, as well as severe liver toxicity, pancreatitis, and profound reductions in blood cell counts. Regular monitoring of ECG, liver function tests and complete blood counts is recommended.

Nilotinib is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients, and in individuals with a history of prolonged QT interval or uncontrolled cardiac arrhythmias. It should also be avoided in patients taking strong CYP3A4 inhibitors without dose adjustment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nilotinib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT